DHT and Hair Loss: Understanding Androgenetic Alopecia

Quick answer: DHT and Hair Loss are strongly linked in androgenetic alopecia, often called male or female pattern baldness. Dihydrotestosterone (DHT), a hormone derived from testosterone, binds to receptors in genetically susceptible hair follicles, causing them to shrink progressively. This leads to finer, shorter hair over time and eventually to visible hair thinning or baldness, though not all hair loss is caused by DHT.

Key takeaways

• DHT (dihydrotestosterone) is a hormone converted from testosterone, playing a significant role in androgenetic alopecia.
• Genetically sensitive hair follicles react to DHT by miniaturising, producing finer, shorter hair.
• Androgenetic alopecia is the most common form of hair loss, affecting both men and women, and is hereditary.
• The enzyme 5-alpha reductase converts testosterone to DHT; its activity influences the extent of DHT's impact.
• Not all hair loss is caused by DHT; other conditions like telogen effluvium or alopecia areata have different origins.
• Professional diagnosis is crucial to determine the specific cause of hair loss and guide effective management.

DHT and Hair Loss: what the evidence shows

DHT (dihydrotestosterone) is a potent androgen, a male sex hormone present in both men and women, derived from testosterone. It is a critical factor in the development of androgenetic alopecia, the most common form of hair loss worldwide. Androgenetic alopecia is a progressive condition characterised by the gradual miniaturisation of hair follicles, leading to shorter, thinner, and eventually absent hair.

The link between DHT and Hair Loss stems from DHT's interaction with specific androgen receptors located within hair follicles. When DHT binds to these receptors in genetically predisposed individuals, it triggers a cascade of events that shorten the anagen (growth) phase of the hair cycle and prolong the telogen (resting) phase. Over successive cycles, the hair shaft becomes progressively thinner and shorter, a process known as follicular miniaturisation. Ultimately, the follicle may cease producing terminal (thick, pigmented) hair altogether, replacing it with vellus (fine, colourless) hair or becoming inactive.

The mechanism of DHT in hair loss

Testosterone, the precursor to DHT, is converted into DHT by an enzyme called 5-alpha reductase (5-AR). There are two primary types of this enzyme:

• 5-alpha reductase Type 1: Found throughout the body, including the skin and sebaceous glands.
• 5-alpha reductase Type 2: Primarily located in the prostate, seminal vesicles, and, significantly, in the inner root sheath of hair follicles.

It is predominantly the activity of 5-alpha reductase Type 2 within the hair follicle that leads to the local production of DHT, which then acts on sensitive follicles. The genetic predisposition to androgenetic alopecia involves inherited variations that make certain hair follicles more sensitive to DHT or influence the activity of 5-alpha reductase. For example, hair follicles on the back and sides of the scalp are typically resistant to DHT's effects, which is why they are often preserved even in advanced cases of pattern baldness.

Androgenetic alopecia in men and women

• Male Pattern Baldness: In men, androgenetic alopecia typically presents as a receding hairline (often forming an M-shape) and/or thinning on the crown or vertex of the head. This pattern is directly linked to the distribution of DHT-sensitive follicles.
• Female Pattern Hair Loss (FPHL): In women, androgenetic alopecia usually manifests as a diffuse thinning over the top and crown of the scalp, often with the frontal hairline remaining intact. While DHT plays a role, the hormonal mechanisms in FPHL are more complex, involving a broader interplay of androgens, oestrogens, and genetic factors. The presentation can vary, with some women experiencing a Christmas tree pattern of thinning.

What the evidence does not show

While the role of DHT in androgenetic alopecia is well-established, it is important to clarify what the evidence does not support:

• DHT does not cause all types of hair loss. Many other conditions, such as telogen effluvium (excessive hair shedding due to stress, illness, or hormonal changes), alopecia areata (an autoimmune condition), or traction alopecia (hair loss from prolonged pulling), are not primarily driven by DHT. Misattributing these to DHT can lead to ineffective treatments.
• Dietary factors are not proven to directly impact DHT levels sufficiently to reverse androgenetic alopecia. While a healthy, balanced diet supports overall hair health, there is no scientific consensus that specific foods can significantly lower scalp DHT levels or cure androgenetic alopecia.
• Cosmetic products alone cannot block DHT to treat androgenetic alopecia. While some shampoos or conditioners might support scalp health, they do not possess the pharmaceutical action required to inhibit 5-alpha reductase or block DHT receptors effectively enough to halt or reverse progressive hair miniaturisation. Their benefits are cosmetic, contributing to healthier-looking hair and scalp.

Signs and symptoms of DHT-related hair loss

Recognising the signs of androgenetic alopecia can help in early intervention. The key indicator is the progressive miniaturisation of hair follicles, leading to noticeable changes in hair quality and density.

Characteristic	Male Pattern Baldness (MPB)	Female Pattern Hair Loss (FPHL)
Pattern of Hair Loss	Receding hairline, thinning at the crown/vertex.	Diffuse thinning over the top/crown; frontal hairline often preserved.
Hair Texture	Hair becomes finer, shorter, less pigmented.	Hair becomes finer, shorter, less pigmented.
Onset	Can begin in late teens, usually progresses with age.	Often noticeable after puberty, can worsen with hormonal changes (e.g., menopause).
Scalp Visibility	Scalp becomes increasingly visible, especially at the temples and crown.	Scalp becomes visible, often through a widening part line.
Progression	Gradual, predictable progression.	Slower, less predictable progression than MPB, but still gradual.

When to seek professional advice

If you are experiencing noticeable hair thinning or hair loss, it is advisable to consult a healthcare professional, such as a dermatologist or trichologist. They can accurately diagnose the cause of your hair loss, distinguish between androgenetic alopecia and other conditions, and discuss appropriate management options. Early diagnosis can be crucial for effective management of DHT and Hair Loss.

Frequently asked questions about DHT and Hair Loss

Can diet affect DHT levels?

While a balanced diet is essential for overall health, including hair health, there is no strong scientific evidence that specific dietary changes can significantly reduce DHT levels in the scalp or reverse androgenetic alopecia. Nutritional deficiencies can impact hair, but addressing these is different from altering hormone levels to treat DHT-related hair loss.

Is DHT-related hair loss reversible?

While complete reversal of severe, long-standing DHT-related hair loss is challenging, treatment can often halt its progression and, in some cases, lead to partial regrowth. Early intervention is key. Treatments typically focus on reducing DHT's effects or stimulating follicle growth, but consistent, long-term adherence is usually required.

Does stress increase DHT and hair loss?

Stress is more commonly linked to other forms of hair shedding, such as telogen effluvium, where significant emotional or physical stress can prematurely push a large number of hairs into the resting phase. While chronic stress can affect overall hormonal balance, there's no direct evidence to suggest it significantly increases scalp DHT levels leading to androgenetic alopecia.

Are there natural ways to block DHT?

Some botanical extracts, like saw palmetto and rosemary oil, have been studied for potential 5-alpha reductase inhibiting properties, though research is ongoing and often limited. For example, some studies suggest rosemary extract may have benefits for hair growth, as discussed in our article on Rosemary Extract: Understanding Its Role in Haircare. However, their efficacy compared to pharmaceutical treatments for androgenetic alopecia is not as robustly established.

What are the main treatments for DHT-related hair loss?

The primary medically recognised treatments for DHT-related hair loss include topical minoxidil, which stimulates hair growth, and oral finasteride or dutasteride, which inhibit the 5-alpha reductase enzyme to reduce DHT production. These treatments are often prescribed by healthcare professionals and can significantly slow progression or encourage regrowth.

Conclusion

Understanding the intricate relationship between DHT and Hair Loss is fundamental to addressing androgenetic alopecia effectively. DHT's action on genetically susceptible hair follicles leads to miniaturisation, resulting in the common patterns of male and female pattern baldness. While pharmaceutical interventions target DHT directly, supporting overall scalp health and managing expectations about cosmetic products are also important. For any concerns about hair loss, professional diagnosis is always the recommended first step.

Where Watermans fits

Watermans formulations are designed to support a healthy scalp environment and promote the appearance of thicker, fuller hair. Ingredients such as hydrolysed lupin protein are included for their potential to help fortify the hair fibre and support scalp vitality. While cosmetic products do not treat or cure androgenetic alopecia, a healthy scalp is a better foundation for hair growth. Watermans Grow Me Shampoo and Conditioner are formulated to cleanse gently and provide beneficial ingredients that can contribute to stronger-feeling, fuller-looking hair and a healthier scalp. They do not claim to inhibit DHT directly, but rather support optimal conditions for hair that looks its best.

Sources and references

• American Academy of Dermatology Association. (n.d.). Hair loss: Diagnosis and treatment. Retrieved from aad.org
• National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). (2016). Alopecia Areata. NIH Publication No. 16-5316.
• NHS. (2023). Hair loss. Retrieved from nhs.uk
• Olsen, E. A. (1999). Androgenetic Alopecia. The New England Journal of Medicine, 341(26), 1965-1972. [DOI: 10.1056/NEJM199912233412607]
• Price, V. H. (2003). Androgenetic Alopecia in Women: Clinical and Hormonal Aspects. Dermatologic Clinics, 21(1), 65-71. [DOI: 10.1016/S0733-8635(02)00078-4]
• Sinclair, R. D. (2004). Male pattern hair loss: a complete guide. Australian Family Physician, 33(11), 903-906. Retrieved from racgp.org.au
• U.S. National Library of Medicine. (n.d.). Dihydrotestosterone. MedlinePlus. Retrieved from medlineplus.gov